Clinical Trial

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Study acronym: AxIn
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2023 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase II open label trial randomized patients who completed the induction with nivolumab plus ipilimumab without complete response or progressive disease will be randomized 1:1 to receive axitinib in addition to nivolumab (Arm A) or continue with nivolumab alone (Arm B).Treatment will be continued until progression of disease, unacceptable toxicity, patient's refusal, or physician decision whichever occurred first.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-05; most recent amendment 2023-05-05.
Status change: Not Yet Recruiting → Recruiting 2023-05-05
Trial Details
NCT Number NCT05817903
Lead Sponsor Consorzio Oncotech
Collaborators: Pfizer
Conditions Metastatic Renal Cell Carcinoma
Enrollment 118 participants
Start Date 2023-04-18
Primary Completion 2026-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2023-05-08